search
Back to results

Electrical Stimulation in Diabetic Peripheral Neuropathy (NERVES)

Primary Purpose

NMES, Control

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
NMES
Sponsored by
Imperial College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for NMES focused on measuring NMES, diabetic peripheral neuropathy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  • 18+ years old
  • Diabetes as defined by WHO diagnostic criteria on best medical therapy
  • Diabetic peripheral polyneuropathy present, confirmed by nerve conduction testing

Exclusion criteria

  • Pregnancy
  • Pacemaker
  • Metal implants in the legs (below knee)

Sites / Locations

  • Academic Vascular Surgery, Charing Cross Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control

NMES

Arm Description

Treated according to local protocol for diabetic peripheral neuropathy

Treated with neuromuscular stimulation of both legs, for 10 weeks

Outcomes

Primary Outcome Measures

Nerve Conduction Speed (Common Peroneal Nerve)

Secondary Outcome Measures

PAID - Quality of Life Questionnaires
PAID (Problem Areas in Diabetes) is a self-administered 20-item scale. Each item is scored from 0 (not a problem) to 4 (serious problem). The sum of all item scores multiplied by 1.25 gives the total PAID score, which ranges from 0 to 100, higher scores reflecting greater emotional distress.

Full Information

First Posted
January 9, 2014
Last Updated
October 5, 2020
Sponsor
Imperial College London
search

1. Study Identification

Unique Protocol Identification Number
NCT02082145
Brief Title
Electrical Stimulation in Diabetic Peripheral Neuropathy
Acronym
NERVES
Official Title
Electrical Stimulation in Diabetic Peripheral Neuropathy
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
July 2014 (Actual)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To assess the effect of the device on the progression of diabetic peripheral neuropathy
Detailed Description
Diabetes is a metabolic disease that affects the body's ability to control blood sugar levels. This affects the tissues of the body, particularly the walls of blood vessels. People with diabetes are more likely to suffer from ischaemic heart disease, stroke, kidney problems, blindness, foot ulcers, and peripheral nerve problems. Diabetes affects approximately 347 million people worldwide, and by 2030 the WHO projects that complications of diabetes will be the 7th leading cause of death. Peripheral neuropathy is a dysfunction of the nerves most commonly affecting the arms and legs. Diabetes is the leading cause of neuropathy in the Western world, and diabetic neuropathy is estimated to affect between 20-50% of diabetic people. The American Diabetes Association define it as the 'presence of symptoms and signs of peripheral nerve dysfunction in patients with diabetes after exclusion of other causes'. As regards complications of diabetes, peripheral neuropathy has the greatest detrimental effect on quality of life. Diabetic neuropathy is implicated in 50-75% of non-traumatic amputations. The device to be tested mimics the effect of walking by stimulating the motor nerves of the leg, making the foot twitch- it increases blood flow to the limb and exercises the leg muscles. We have seen previous clinical cases of improvement in peripheral neuropathy with use of the device, and wish to formalise the benefits to patients. It is hypothesised to work either by increasing blood flow to the limb and therefore the nerves themselves, or for electrical current to be having a direct effect on the peripheral nervous system itself. The device is easily fitted, can be self-administered by patients, and is suitable for out-patient therapy. We wish to evaluate both the short- and longer-term effects of a neuromuscular stimulator on diabetic peripheral neuropathy as a therapeutic intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
NMES, Control
Keywords
NMES, diabetic peripheral neuropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
14 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
Treated according to local protocol for diabetic peripheral neuropathy
Arm Title
NMES
Arm Type
Experimental
Arm Description
Treated with neuromuscular stimulation of both legs, for 10 weeks
Intervention Type
Device
Intervention Name(s)
NMES
Intervention Description
Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
Primary Outcome Measure Information:
Title
Nerve Conduction Speed (Common Peroneal Nerve)
Time Frame
Baseline, 10 weeks
Secondary Outcome Measure Information:
Title
PAID - Quality of Life Questionnaires
Description
PAID (Problem Areas in Diabetes) is a self-administered 20-item scale. Each item is scored from 0 (not a problem) to 4 (serious problem). The sum of all item scores multiplied by 1.25 gives the total PAID score, which ranges from 0 to 100, higher scores reflecting greater emotional distress.
Time Frame
Baseline, 10 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria 18+ years old Diabetes as defined by WHO diagnostic criteria on best medical therapy Diabetic peripheral polyneuropathy present, confirmed by nerve conduction testing Exclusion criteria Pregnancy Pacemaker Metal implants in the legs (below knee)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
A H Davies
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Academic Vascular Surgery, Charing Cross Hospital
City
London
ZIP/Postal Code
W6 8RF
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22717465
Citation
Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, Sharma NK, Wright DE. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications. 2012 Sep-Oct;26(5):424-9. doi: 10.1016/j.jdiacomp.2012.05.007. Epub 2012 Jun 18.
Results Reference
background
PubMed Identifier
16798472
Citation
Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, Fallucca F. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006 Jul-Aug;20(4):216-23. doi: 10.1016/j.jdiacomp.2005.07.005.
Results Reference
background

Learn more about this trial

Electrical Stimulation in Diabetic Peripheral Neuropathy

We'll reach out to this number within 24 hrs